Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma
Status:
Completed
Trial end date:
2017-09-13
Target enrollment:
Participant gender:
Summary
The purpose of this study:
Determining the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), pharmacokinetics
characteristic, and dosage regimen of phase II/III of Chlorogenic acid for injection in the
advanced Glioblastoma Patients ;
Phase:
Phase 1
Details
Lead Sponsor:
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
Collaborators:
Beijing Shijitan Hospital Beijing Shijitan Hospital, Capital Medical University